BIG
CTKB icon

Brooklyn Investment Group’s Cytek Biosciences CTKB Stock Holding History

Brooklyn Investment Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,452
Closed -$101K – 1512
2025
Q3 		$101K Sell
28,452
-2,212
-7% -$8.3K 0.01% 640
2025
Q2 		$104K Buy
30,664
+20,741
+209% +$69.1K 0.01% 916
2025
Q1 		$39.8K Buy
9,923
+9,922
+992,200% +$51.4K 0.01% 884
2024
Q4 		$7 Buy
+1
New +$6 ﹤0.01% 1932

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Brooklyn Investment Group's CTKB Position: Q4 2025 in Review

Brooklyn Investment Group sold out of Cytek Biosciences (CTKB) in Q4 2025, closing a stake of 28,452 shares — an estimated $101K sold.

Brooklyn Investment Group first reported a position in CTKB in Q4 2024 and held it in 4 quarters. The position peaked at $104K in Q2 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q4 2025.

  • Brooklyn Investment Group reported no remaining Cytek Biosciences position as of Q4 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 28,452 Cytek Biosciences shares in Q4 2025, an estimated $101K.
  • Brooklyn Investment Group first reported a position in Cytek Biosciences in Q4 2024 and held it in 4 quarters.
  • Brooklyn Investment Group's Cytek Biosciences position peaked at $104K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2025.

Based on Brooklyn Investment Group's 13F filing for Q4 2025, filed 12 Feb 2026.